Compare ESTC & CRSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ESTC | CRSP |
|---|---|---|
| Founded | 2012 | 2013 |
| Country | Netherlands | Switzerland |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.6B | 4.9B |
| IPO Year | 2018 | 2016 |
| Metric | ESTC | CRSP |
|---|---|---|
| Price | $51.82 | $54.67 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 28 | 17 |
| Target Price | ★ $91.38 | $70.29 |
| AVG Volume (30 Days) | 1.4M | ★ 1.7M |
| Earning Date | 05-28-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,483,296,000.00 | $289,590,000.00 |
| Revenue This Year | $19.06 | $807.72 |
| Revenue Next Year | $13.42 | $172.52 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 17.04 | ★ 9169.85 |
| 52 Week Low | $42.05 | $34.87 |
| 52 Week High | $96.07 | $78.48 |
| Indicator | ESTC | CRSP |
|---|---|---|
| Relative Strength Index (RSI) | 57.66 | 54.56 |
| Support Level | $49.44 | $50.91 |
| Resistance Level | $51.91 | $55.30 |
| Average True Range (ATR) | 2.20 | 3.02 |
| MACD | 0.74 | -0.04 |
| Stochastic Oscillator | 83.04 | 58.44 |
Elastic is a software company that specializes in AI-search, observability, and security deployments. Its search division offers both traditional keyword search and vector search methods to enable more context-aware querying. The software has open-source origins but generates revenue through valuable add-ons, including simplified data orchestration and server scaling techniques.
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.